• Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    • Lee JM, Moore RG, Ghamande S, Park MS, Diaz JP, Chapman J, Kendrick J, Slomovitz BM, Tewari KS, Lowe ES, Milenkova T, Kumar S, Dymond M, Brown J, Liu JF.
    • Clin Cancer Res. 2022 Aug 2:CCR-21-1733. doi: 10.1158/1078-0432.CCR-21-1733. Epub ahead of print.